Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Pseudoxanthoma Elasticum: early-phase trial registry
2 of 4 indexed Pseudoxanthoma Elasticum trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #4,115 of 28,707 conditions by registered trial count.
4 US clinical trials · 2 currently recruiting · #4,115 of 28,707 conditions by registered trial count
Pseudoxanthoma Elasticum: 4 US clinical trials tracked, 2 recruiting.
Pseudoxanthoma Elasticum is the subject of 4 registered US clinical trials on ClinicalTrials.gov, 2 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 3 in Phase 1-2 (earlier-stage). The most active sponsor is Inozyme Pharma, running 2 of these trials.
Enrollment posture brief
Registry condition pseudoxanthoma-elasticum
OPEN 2 | RECR 50% | LATE 0 | EARLY 3 | RANK #4115 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Abdominal Aortic Aneurysms (50% recruiting · 6 trials)
Pseudoxanthoma Elasticum lists 2 open slots (50% of 4 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Pseudoxanthoma Elasticum on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Pseudoxanthoma Elasticum is recruiting above its size-band peers.
2 of 4 indexed trials (50%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Open and recent trials
4 total, page 1 of 1
ADAPT Study: Long-term Safety Study of INZ-701 in Patients With ENPP1 Deficiency and ABCC6 Deficiency
Inozyme Pharma
NCT06462547
The ENERGY Study: Evaluation of Safety and Tolerability of INZ-701 in Infants With ENPP1 Deficiency or ABCC6 Deficiency
Inozyme Pharma
NCT05734196
Genetic Analysis of Patients With Pseudoxanthoma Elasticum
National Cancer Institute (NCI)
NCT00341419
A Study of DS-1211b in Individuals With PseudoXanthoma Elasticum
Daiichi Sankyo
NCT05569252
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
| Phase 2 | 2 |
Top Sponsors
Named interventions
Most-linked intervention names on Pseudoxanthoma Elasticum records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Pseudoxanthoma Elasticum trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Pseudoxanthoma Elasticum page
4 registered trials, 2 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 2 Pseudoxanthoma Elasticum trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Inozyme Pharma sponsors the most Pseudoxanthoma Elasticum trials on record, review their full trial history before evaluating a specific study. See Inozyme Pharma's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Pseudoxanthoma Elasticum condition card totals 4 registered trials; most-linked intervention INZ-701; top US site state Pennsylvania. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.